PE97699A1 - Macrolidas cristalinas - Google Patents

Macrolidas cristalinas

Info

Publication number
PE97699A1
PE97699A1 PE1998000568A PE00056898A PE97699A1 PE 97699 A1 PE97699 A1 PE 97699A1 PE 1998000568 A PE1998000568 A PE 1998000568A PE 00056898 A PE00056898 A PE 00056898A PE 97699 A1 PE97699 A1 PE 97699A1
Authority
PE
Peru
Prior art keywords
crystalline form
crystalline
refers
formula
macrolides
Prior art date
Application number
PE1998000568A
Other languages
English (en)
Inventor
Cornelia Dosenbach
Maximilian Grassberger
Otto Hartmann
Amarylla Horvath
Jean-Paul Mutz
Gerhard Penn
Sabine Pfeffer
Dierk Wieckhusen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10815103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE97699(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE97699A1 publication Critical patent/PE97699A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Metallurgy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A UNA FORMA CRISTALINA DE 33-EPICLORO-33-DESOXIASCOMICINA DE FORMULA (I) O SUS FORMAS TAUTOMERICAS O SOLVATADAS, LA QUE PUEDE ESTAR COMO LA FORMA CRISTALINA A O LA FORMA CRISTALINA B. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION QUE COMPRENDE CONVERTIR EL COMPUESTO AMORFO DE FORMULA (I) A PARTIR DE UNA SOLUCION, BAJO CONDICIONES INDUCTORAS DE CRISTALIZACION DE PREFERENCIA DE LA FORMA A Y DE LA FORMA B
PE1998000568A 1997-06-30 1998-06-26 Macrolidas cristalinas PE97699A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9713730.1A GB9713730D0 (en) 1997-06-30 1997-06-30 Organic compounds

Publications (1)

Publication Number Publication Date
PE97699A1 true PE97699A1 (es) 1999-10-29

Family

ID=10815103

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000568A PE97699A1 (es) 1997-06-30 1998-06-26 Macrolidas cristalinas

Country Status (32)

Country Link
US (1) US6423722B1 (es)
EP (1) EP0994880B1 (es)
JP (2) JP3880634B2 (es)
KR (1) KR100399765B1 (es)
CN (1) CN1139595C (es)
AR (1) AR017754A1 (es)
AT (1) ATE287410T1 (es)
AU (1) AU739211B2 (es)
BR (1) BR9810956A (es)
CA (1) CA2290412C (es)
CO (1) CO4940463A1 (es)
CZ (1) CZ297244B6 (es)
DE (1) DE69828692T2 (es)
DK (1) DK0994880T3 (es)
ES (1) ES2236922T3 (es)
GB (1) GB9713730D0 (es)
HK (1) HK1028597A1 (es)
HU (1) HU227755B1 (es)
ID (1) ID24897A (es)
IL (1) IL132761A0 (es)
MY (1) MY118718A (es)
NO (1) NO312765B1 (es)
NZ (1) NZ500994A (es)
PE (1) PE97699A1 (es)
PL (1) PL192761B1 (es)
PT (1) PT994880E (es)
RU (1) RU2219181C2 (es)
SK (1) SK285665B6 (es)
TR (1) TR199903189T2 (es)
TW (1) TW552264B (es)
WO (1) WO1999001458A1 (es)
ZA (1) ZA985655B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9713730D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
GB0125443D0 (en) * 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
DE602004024417D1 (de) * 2003-09-03 2010-01-14 Glaxo Group Ltd Neues verfahren zur herstellung von pleuromutilinderivaten
WO2006060616A1 (en) * 2004-12-01 2006-06-08 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Processes for producing crystalline macrolides
TW200837067A (en) * 2006-11-06 2008-09-16 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Ascomycin and pimecrolimus having reduced levels of desmethylascomycin and 32-deoxy-32-epichloro-desmethylascomycin respectively, and methods for preparation thereof
US20100105724A1 (en) * 2006-12-07 2010-04-29 Helsinn Healthcare Sa Crystalline and amorphous forms of palonosetron hydrochloride
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
ES2550634T3 (es) 2009-07-10 2015-11-11 Boston Scientific Scimed, Inc. Uso de nanocristales para un balón de suministro de fármaco
JP5933434B2 (ja) 2009-07-17 2016-06-08 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 薬剤送達バルーンの製造方法
WO2012031236A1 (en) 2010-09-02 2012-03-08 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
WO2013022458A1 (en) * 2011-08-05 2013-02-14 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
WO2013028208A1 (en) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
CN105102967B (zh) 2013-03-15 2018-10-12 生物传感器国际集团有限公司 雷帕霉素衍生物的纯化
EP3178824A1 (en) 2015-12-08 2017-06-14 Medichem, S.A. Process for preparing pimecrolimus
KR102592374B1 (ko) * 2017-05-01 2023-10-25 메다 파마 게엠베하 운트 코. 카게 조질의 아스코마이신을 정제된 피메크롤리무스로 전환하는 방법
EP3741367A1 (en) 2019-05-21 2020-11-25 Premark Pharma GmbH Treatment of ocular disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51118816A (en) * 1975-04-08 1976-10-19 Meiji Seika Kaisha Ltd A process for stabilizing non-crystalloidal solid
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
GB2084580B (en) 1980-10-01 1984-07-04 Glaxo Group Ltd Aminoalkyl furan derivative
JP2728482B2 (ja) * 1989-01-26 1998-03-18 協和醗酵工業株式会社 マクロライド系抗生物質の精製法
DE69013305T2 (de) 1989-07-10 1995-05-18 Chemferm Vof Stabile form von cephradin, verfahren zu dessen herstellung und darin verwendete zwischenprodukte.
NZ235991A (en) * 1989-11-09 1993-05-26 Sandoz Ltd Macrolide compounds and pharmaceutical compositions thereof
IE910847A1 (en) * 1990-03-13 1991-09-25 Fisons Plc Immunosuppressive macrocyclic compounds
EP0480623A1 (en) * 1990-10-11 1992-04-15 Merck & Co. Inc. New halomacrolides and derivatives having immunosuppressive activity
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
JP2508949B2 (ja) 1991-07-30 1996-06-19 味の素株式会社 Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶及びその製造法
US5247076A (en) 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5221740A (en) 1992-01-16 1993-06-22 American Home Products Corporation Oxepane isomers of rapamycin useful as immunosuppressive agents
UA41884C2 (uk) * 1993-11-05 2001-10-15 Амерікан Хоум Продактс Корпорейшн Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів
US5626757A (en) * 1994-02-22 1997-05-06 Advanced Separation Technologies Inc. Macrocyclic antibiotics as separation agents
EP0848717A1 (en) * 1995-08-24 1998-06-24 Merck & Co., Inc. Process for the preparation of imidazolyl macrolide immunosuppressants
GB9713730D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds

Also Published As

Publication number Publication date
DE69828692T2 (de) 2006-01-12
ATE287410T1 (de) 2005-02-15
GB9713730D0 (en) 1997-09-03
HUP0003053A2 (hu) 2001-02-28
CN1139595C (zh) 2004-02-25
ES2236922T3 (es) 2005-07-16
EP0994880A1 (en) 2000-04-26
HUP0003053A3 (en) 2003-03-28
PL192761B1 (pl) 2006-12-29
JP2006151999A (ja) 2006-06-15
PT994880E (pt) 2005-06-30
EP0994880B1 (en) 2005-01-19
DE69828692D1 (de) 2005-02-24
ZA985655B (en) 1998-12-30
RU2219181C2 (ru) 2003-12-20
CA2290412C (en) 2009-11-10
BR9810956A (pt) 2000-09-26
ID24897A (id) 2000-08-31
NO995909L (no) 1999-12-02
SK186699A3 (en) 2000-05-16
JP3880634B2 (ja) 2007-02-14
US6423722B1 (en) 2002-07-23
NO312765B1 (no) 2002-07-01
JP4504323B2 (ja) 2010-07-14
AU739211B2 (en) 2001-10-04
SK285665B6 (sk) 2007-05-03
CZ474099A3 (cs) 2000-04-12
IL132761A0 (en) 2001-03-19
NO995909D0 (no) 1999-12-02
NZ500994A (en) 2001-08-31
WO1999001458A1 (en) 1999-01-14
DK0994880T3 (da) 2005-05-30
AU8540998A (en) 1999-01-25
HK1028597A1 (en) 2001-02-23
MY118718A (en) 2005-01-31
JP2001506279A (ja) 2001-05-15
CA2290412A1 (en) 1999-01-14
CN1261365A (zh) 2000-07-26
HU227755B1 (en) 2012-02-28
TR199903189T2 (xx) 2000-06-21
CO4940463A1 (es) 2000-07-24
TW552264B (en) 2003-09-11
KR100399765B1 (ko) 2003-09-29
PL336719A1 (en) 2000-07-03
KR20010020423A (ko) 2001-03-15
AR017754A1 (es) 2001-10-24
CZ297244B6 (cs) 2006-10-11

Similar Documents

Publication Publication Date Title
PE97699A1 (es) Macrolidas cristalinas
AR077416A2 (es) Compuesto polimorfo estable de flibanserina , procedimiento industrial para su preparacion y uso del mismo para preparar medicamentos
AR026433A1 (es) Variantes de alfa-amilasa tipo fungamyl
ATE552985T1 (de) Abbildungssystem
AR039666A2 (es) Procedimiento para la preparacion de la forma i de 6-o-metileritromicina a al vacio, dicho compuesto cristalino aislado asi como sus derivados, el uso de los mismos para la preparacion de un antibiotico, el uso de la forma 0 para prepararla forma i de 6-o-metileritromicina a y otros derivados
IS7197A (is) Gormlaga hydantoín efnasambönd, sem gagnleg eru sem bólgueyðandi efni
GT199900055A (es) Nuevas dihidropirimidinas2 heterocìclicamente sustituidas.
CY1105187T1 (el) Κρυσταλλωση υλικων απο υδατικα διαλυματα
BRPI0411268B8 (pt) processo para a preparação de compostos 3-aril butil-amina substituído
ES2188016T3 (es) Derivaqdo de benzamidoxima, productos intermedios y procedimiento para su obtencion y su empleo como fungicidas.
ATE403429T1 (de) Spiropyrazol-verbindungen
ECSP034865A (es) Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
EP1267369A3 (en) Pyridine compound, its use as charge transfer material, and photoelectrochemical cell
EE200000584A (et) Viirusevastase bensimidasoolühendi kristallilisedvormid
EA200200819A1 (ru) Кристаллическая форма ii линезолида
GT200200069A (es) Derivados de mercaptoacetilamida, procedimiento para su preparacion y su uso
TW200617144A (en) Oxynitride phosphor and light-emitting device
ES2159347T3 (es) Naftil-acetamidas como inhibidores de spla2.
ES2166972T3 (es) Procedimiento para preparar alfa-hidroxiacidos libres a partir de sus sales amonicas.
SV1999000052A (es) Triciclicos substituidos ref. x-12144
NO20030182D0 (no) Dermalt påföringssystem for aminolevulinsyre
WO2002028855A3 (en) Amorphous form of cell cycle inhibitor
PE20010644A1 (es) Procesos para la produccion de acidos 2-fenilamino-5-alquilfenilaceticos
AR048099A1 (es) FORMA CRISTALINA DE ÁCIDO 8-CIANO-1CICLOPROPIL-7-(1S,6S-2,8-DIAZABICICLO)(4.3.0)NONAN--IL)-6FLUOR-1,4-DIHIDRO-4-OXO-3-QUINOLINCARBOXíLICO
BR9917001A (pt) Conversão de compostos de inibição de cox quenão são inibidores seletivos de cox-2 em derivadosque são inibidores seletivos de cox-2

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term